All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EVT894
Therapeutic Area: Infections and Infectious Diseases Product Name: SAR440894
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
EVT894 is a fully human monoclonal antibody that targets a viral protein and has shown potent neutralising activity in in vitro and in vivo models. First Dose of Evt894, a Monoclonal Antibody Against Chikungunya Virus Administered to A Healthy Participant IN A Phase I Study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MVA-SARS-2-S vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
Details:
The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: German Federal Ministry of Education and Research
Deal Size: $297.8 million Upfront Cash: Undisclosed
Deal Type: Funding September 04, 2020
Details:
Funding will support the development of its COVID-19 vaccine candidate. In July 2020, CureVac had applied to a grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 10, 2020
Details:
The net proceeds will support Company’s mRNA vaccine program against SARS-CoV-2 through the completion of Phase 3; will be used to fund the expansion of the Company’s short term manufacturing capabilities; to advance the Company’s lead oncology program, CV8102.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2020
Details:
The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Tesla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 02, 2020
Details:
CureVac has reportedly snared a big partner to help build its game-changing RNA "printers" that could turn global interest back in its favor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Temasek
Deal Size: $250.0 million Upfront Cash: $139.0 million
Deal Type: Funding June 29, 2020
Details:
BioNTech is expected to post data from its Phase I/II trial virtually any day now, as analysts expect some hard numbers on immunogenicity and safety for BNT162 in the June/July time frame.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for CureVac's vaccine program to prevent SARS-CoV-2 infection.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
